In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...
New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around two-thirds of participants of the SURMOUNT-1 trial had only regained 5% or less ...
New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, ...
Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results